Metformin induced acute pancreatitis precipitated by renal failure

S Mallick

Metformin is a biguanide commonly used in type 2 diabetes and considered to be a safe drug with minimal side effects. Approximately 2% of cases of acute pancreatitis may be caused by drugs, but it is not a known complication of metformin therapy. To date only one case of pancreatitis has been reported in association with metformin, but that was secondary to metformin poisoning (overdose). This is the first reported case of pancreatitis caused by a therapeutic dose of metformin (although in this case renal failure precipitated the metformin toxicity). Severe lactic acidosis is a rare but life threatening complication of metformin, which occurs particularly in patients with renal failure.

A 61 year old woman presented to the emergency department with a history of vomiting for four days and abdominal pain for one day. Her medical history included type 2 diabetes, ischaemic heart disease, and previous myocardial infarction, and regular medications included aspirin, atenolol, clopidogrel, amlodipine, lisinopril, nitrate, metformin, nateglinide, and ibuprofen. Owing to vomiting, she had stopped taking most of her medications except the antidiabetic drugs. On clinical examination she looked dry and afebrile, and her initial blood pressure was 110/50 mm Hg, her pulse rate was 50 beats/min and regular, and she had an oxygen saturation of 98% on 2 l of oxygen. Abdominal examination revealed epigastric tenderness without guarding or rigidity. Blood tests showed haemoglobin of 129 g/l, a white cell count of 11.8×10⁹/l, urea of 28.8 mmol/l, creatinine of 516 umol/l, sodium of 145 mmol/l, potassium of 6.7 mmol/l, chloride of 95 mmol/l, glucose of 9 mmol/l, and lactate of 25 mmol/l. Arterial blood gases showed a pH of 7.0 and an anion gap of 43 mmol/l. A liver function test was grossly normal. Amylase was raised at 250 U/l, and this subsequently increased to 769 U/l. Computed tomography of the abdomen was suggestive of pancreatitis. Her renal function had been checked one month previously and had been normal, and her glycated haemoglobin was 5.9%.

She deteriorated further in the emergency department, with blood pressure dropping to 65/50 mm Hg and a urine output of less than 5 ml/hour. Bicarbonate infusion did not improve her acidosis. She was transferred to the intensive care unit and treated with intravenous fluids, inotrope, insulin, and haemodialysis with bicarbonate buffer replacement fluid. All medications were discontinued. Lactic acidosis resolved following haemodialysis, and her amylase returned to a normal level.

DISCUSSION

This woman was diagnosed with drug (angiotensin converting enzyme inhibitor, non-steroidal anti-inflammatory drug) induced renal failure, which reduced excretion of metformin, causing toxicity leading to severe lactic acidosis and pancreatitis.

Severe lactic acidosis is a rare but life threatening complication of metformin therapy, occurring particularly in patients with relative contraindications to the drug (renal dysfunction, alcohol abuse, or liver disease). The mortality rate of metformin associated lactic acidosis is about 50%, although available data show that neither arterial lactate level nor plasma metformin concentration are of prognostic significance.

The common causes of pancreatitis, such as gall stones, alcohol abuse, hypercalcaemia, hypertriglyceridaemia, and trauma, were excluded in this case. A number of drugs (thiazides, azathioprine, oestrogens, sulfonamides, furosemide, etc) can cause pancreatitis and are thought to be responsible for approximately 2% of pancreatitis in adults. None of these drugs was consumed by this patient except for an angiotensin converting enzyme inhibitor, which is occasionally associated with pancreatitis, but it is not a known complication of metformin therapy. To date only one case of pancreatitis has been reported in association with metformin, but that was secondary to metformin poisoning (overdose). Available evidence suggests that acute pancreatitis in this patient was probably precipitated by metformin toxicity. The exact mechanism is not known, but toxicity is probably secondary to acinar cell injury leading to intercellular leakage of digestive enzymes from ductules. Cessation of the drug allowed resolution of the pancreatitis.

CONCLUSIONS

1. Metformin should be prescribed with caution (with regular monitoring of renal function) or, preferably, avoided in patients on other nephrotoxic drugs.
2. Patients with severe lactic acidosis (secondary to metformin) should be promptly referred for haemodialysis.
3. Amylase levels should be measured in this group of patients. Metformin and other drugs should be discontinued in patients with pancreatitis with no identifiable cause.

Correspondence to: Dr Srikumar Mallick, srikumarmallick@hotmail.com

Submitted 29 January 2003
Accepted 1 August 2003

REFERENCES

3 Borgia MC, Celestini A, Caravella P, et al. Angiotensin-converting-enzyme inhibitor administration must be monitored for serum amylase and lipase in...
Wound botulism

A 46 year old man presented with a five day history of nausea and vomiting, blurred vision, slurred speech, and generalised weakness. Two days before admission, he developed diplopia and difficulty breathing. He was an intravenous and subcutaneous, that is, “skin popping” user of black tar heroin, and he was positive for hepatitis C. In the intensive care unit, he was conscious and able to obey commands, although intubated. He had bilateral ptosis and almost complete ophthalmoplegia in all directions (fig 1). Pupils were 4 mm in diameter, responded sluggishly to light. Bilateral facial weakness was observed. He had mild symmetrical proximal weakness, worse on the right. Reflexes were depressed with flexor plantars. Skin examination showed multiple scars from subcutaneous drug injections with track marks and skin popping lesions (fig 2). Cerebrospinal fluid analysis revealed no white cells and normal protein. Mouse bioassay confirmed *Clostridium botulinum* type A toxin. He received antitoxin treatment and improved gradually.

Although California has the infamous distinction of reporting the most wound botulism cases in the world, the disease has been increasingly recognised elsewhere due to the widespread use of subcutaneous black tar heroin.1 This life threatening infection with severe morbidity should be considered in all patients with history of subcutaneous drug use presenting with generalised weakness. Ophthalmoparesis with sluggish pupils and bulbar dysfunction are important clues to the diagnosis. In addition to supportive measures, searches for abscess and antibiotics are the mainstay of treatment. Antitoxin treatment has been reported to shorten hospital stays with fewer days on ventilatory support.

Correspondence to: Dr R Bhidayasiri, Department of Neurology, Reed Neurological Research Institute, UCLA Medical Center, 710 Westwood Plaza, Los Angeles, CA 90095, USA; rbh@ucla.edu

**REFERENCES**


**Figure 1** The patient had bilateral proptosis and almost complete ophthalmoplegia in all directions. In addition, bilateral facial weakness was noted (arrows correspond to attempts on direction of gaze).

**Figure 2** Skin examination of his right leg demonstrated multiple scars from subcutaneous drug injections with track marks and skin popping lesions.
Metformin induced acute pancreatitis precipitated by renal failure

S Mallick

doi: 10.1136/pgmj.2003.011957

Updated information and services can be found at:
http://pmj.bmj.com/content/80/942/239

These include:

References
This article cites 5 articles, 0 of which you can access for free at:
http://pmj.bmj.com/content/80/942/239#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Pancreas and biliary tract (65)
- Pancreatitis (18)
- Urology (110)
- Occupational and environmental medicine (37)
- Diabetes (142)
- Metabolic disorders (221)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/